Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules
| Autor: | J Osorio, SD Portsmouth, Brian Gazzard, GJ Moyle, K McCormick |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Cyclopropanes Male medicine.medical_specialty Efavirenz HIV Infections Drug Administration Schedule Statistics Nonparametric law.invention Zidovudine chemistry.chemical_compound Randomized controlled trial law Antiretroviral Therapy Highly Active Internal medicine Oxazines medicine Humans Pharmacology (medical) business.industry Health Policy Stavudine Lamivudine Middle Aged Viral Load Benzoxazines CD4 Lymphocyte Count Surgery Clinical trial Regimen Infectious Diseases Tolerability chemistry Alkynes Delayed-Action Preparations HIV-1 Quality of Life Patient Compliance Reverse Transcriptase Inhibitors Female business medicine.drug |
| Zdroj: | HIV Medicine. 6:185-190 |
| ISSN: | 1468-1293 1464-2662 |
| DOI: | 10.1111/j.1468-1293.2005.00287.x |
| Popis: | Background Adherence to antiretroviral therapy is critical to treatment outcomes. Adherence studies in other therapeutic areas of medicine suggest that once-daily regimens support improved adherence when compared to twice-daily therapy. An expansion in the range of once-daily antiretrovirals is making once-daily therapy possible for persons with HIV infection. Methods A 24-week randomized open-label simplification study of twice-daily regimens based on stavudine immediate release or zidovudine to an all once-daily regimen based on the stavudine prolonged-release capsule (PRC), in persons with complete virological suppression on regimens also including efavirenz and lamivudine, was carried out. Subjects were assessed for adherence [using the Medication Event Monitoring System® (MEMS®) cap; Aardex Corporation, Union City, CA, USA], quality of life, tolerability and efficacy. Results Forty-three patients were randomly assigned: 21 remained on their original regimen and 22 switched to once-daily therapy with stavudine PRC. Although high levels of adherence and good quality of life were present at study enrolment, adherence declined to a significantly lesser extent at week 24 in the group that switched to once-daily therapy. Efficacy was maintained in both groups and there were no differences in tolerability or toxicity. Conclusions Subjects switching from twice-daily therapy to once-daily therapy demonstrate less of a decline in adherence over 24 weeks. A once-daily regimen including stavudine PRC is as effective and tolerable as a regimen containing the twice-daily formulation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|